Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TQB3909
i
Other names:
TQB3909
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Sino Biopharm
Drug class:
Bcl2 inhibitor
Related drugs:
‹
venetoclax (416)
paclitaxel (178)
albumin-bound paclitaxel (67)
ABT 263 (19)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
ABBV-453 (0)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
BP1002 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TW-37 (0)
ZN-d5 (0)
bisphosphonate bound paclitaxel (0)
FID-007 (0)
GX 15-070 (0)
QR 207 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
venetoclax (416)
paclitaxel (178)
albumin-bound paclitaxel (67)
ABT 263 (19)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
ABBV-453 (0)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
BP1002 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TW-37 (0)
ZN-d5 (0)
bisphosphonate bound paclitaxel (0)
FID-007 (0)
GX 15-070 (0)
QR 207 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
›
Associations
News
Trials
Filter by
Latest
6ms
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
P1/2, N=93, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> May 2024
6 months ago
Enrollment open • Trial initiation date
|
TQB3909 • rovadicitinib (TQ05105)
9ms
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
P1/2, N=93, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
9 months ago
New P1/2 trial
|
TQB3909 • rovadicitinib (TQ05105)
10ms
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy (clinicaltrials.gov)
P1, N=208, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
10 months ago
New P1 trial
|
TQB3909
11ms
A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets (clinicaltrials.gov)
P1, N=40, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
11 months ago
New P1 trial
|
itraconazole • TQB3909 • rifampicin
1year
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
P1/2, N=39, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
1 year ago
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
TQB3909
1year
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (clinicaltrials.gov)
P1/2, N=107, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
1 year ago
Enrollment open
|
PLCG2 (Phospholipase C Gamma 2)
|
TQB3909
over1year
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (clinicaltrials.gov)
P1/2, N=107, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
over 1 year ago
New P1/2 trial
|
PLCG2 (Phospholipase C Gamma 2)
|
TQB3909
over1year
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer (clinicaltrials.gov)
P1/2, N=65, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
over 1 year ago
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
TQB3909
over2years
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=126, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Nov 2021 --> Feb 2022
over 2 years ago
Enrollment open • Trial initiation date • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
TQB3909
3years
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=126, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Aug 2021 --> Nov 2021
3 years ago
Clinical • Trial initiation date • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
TQB3909
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login